A comprehensive and preventative approach to neurodegenerative diseases

Alzheimer’s is a mounting burden on health systems, with global costs projected to pass $2T by 2030.

Care today is largely reactive, arriving when neurological damage is already extensive.

The paper sets out a preventive framework: blood-based biomarkers, AD Prevention Bonds and GLP-1–based neuroprotection.